Saturday 17 October 2026 Export ATYR’s income statement to Excel — free account

aTyr Pharma, Inc.

aTyr Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $190,000.00, down 19.1% from fiscal 2024. In the quarter to June 2026, revenue fell 90.8%, EPS grew 50.0%, free cash flow grew 32.2% and total debt fell 94.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.17 0.01 −5.56%

Follow ATYR

Alert me

Market cap: $18.0M
P/E: 0.0×
Fwd P/E: −0.9×
Dividend yield: —
F-score: 2/9
Altman Z: −9.34
Beneish M: −3.76
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.05

Total sells 0.01

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	1	—	—	—	—	—
Sell	—	—	—	3	—	—	—	—	—	—	—	—

Insider Ownership 4.39%

Capital & Financial Ratios $m

Market Cap 18.03

Revenue 11.16

Net Income (60.81)

Free Cash Flow (54.81)

Net Debt (57.38)

Current Ratio 5.12

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.90)

P/S ratio 1.49

P/B ratio 0.34

Past 5Y EPS Growth —

This Y EPS Growth 43.12%

Next Y EPS Growth 2.47%

Next Y revenue growth 916.32%

Next 5Y EPS Growth 22.90%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.06%

10-year low 10-year high

P/B against its own 10 years 1.18%

10-year low 10-year high

EV/FCF against its own 10 years 84.99%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	98	72	79	57
Receivables	2	2	1	0
Inventory	—	—	—	—
Other	—	—	—	—
	103	82	80	58

	2023	2024	2025	Q'26
Payables	4	4	4	3
ST’ Debt	—	—	—	—
Other	—	—	—	—
	16	15	15	11

Compound Annual Growth %

	10y	5y	3y
Sales	—	(14.75%)	(73.65%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(5.22%)	16.40%	(1.90%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	0	—	0
’24	0	—	—	—	0
’23	—	—	0	—	0
’22	—	—	—	10	10
’20	8	0	0	2	10

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	(9)	—	—	—
’25	(15)	(14)	(20)	(12)	(62)
’24	(22)	(20)	(13)	(13)	(69)
’23	(1)	(12)	(10)	(11)	(33)
’22	(10)	(9)	(12)	(10)	(42)
’21	(6)	(8)	(11)	(8)	(33)
’20	2	(6)	(6)	(5)	(15)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	(9)	—	—	—
’25	(15)	(14)	(21)	(12)	(62)
’24	(22)	(20)	(13)	(13)	(69)
’23	(2)	(14)	(10)	(11)	(37)
’22	(10)	(9)	(13)	(11)	(43)
’21	(6)	(8)	(12)	(8)	(33)
’20	2	(6)	(6)	(5)	(15)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.11)	(0.11)	—	—	—
’25	(0.17)	(0.22)	(0.26)	(0.14)	(0.80)
’24	(0.23)	(0.23)	(0.23)	(0.18)	(0.86)
’23	(0.29)	(0.22)	(0.20)	(0.25)	(0.94)
’22	(0.44)	(0.44)	(0.46)	(0.26)	(1.60)
’21	(0.51)	(0.64)	(0.42)	(0.31)	(1.77)
’20	0.25	(0.69)	(0.68)	(0.47)	(1.77)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	29.40	31.50	5.25	2.76	2.13	3.48	2.00	1.08	1.39	0.64	Analyst estimates 2026–2028 Powerpack
	High	134.82	90.94	59.14	10.08	7.62	13.10	8.25	2.70	3.98	7.29
People
People	Employees	58	65	42	44	43	53	70	59	59	58
	Revenue/emp, $m	0.00	0.00	0.00	0.01	0.24	0.00	0.15	0.01	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	0	10	—	10	0	0	0
	Gross margin, %	0.00	0.00	0.00	100.00	100.00	0.00	100.00	100.00	100.00	100.00
	EBT	(58)	(48)	(35)	(24)	(16)	(34)	(45)	(50)	(64)	(74)
	EBT margin, %	0.00	0.00	0.00	(5,631.04)	(155.24)	0.00	(436.58)	(14,276.77)	(27,243.40)	(39,012.11)
	Net income	(58)	(48)	(35)	(24)	(16)	(34)	(45)	(50)	(64)	(74)
	Depreciation	2	1	1	2	2	2	2	0	(1)	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.13	1.14	0.00	0.37	0.01	0.00	0.00
	Earnings	(34.17)	(26.19)	(16.11)	(7.03)	(1.77)	(1.77)	(1.60)	(0.94)	(0.86)	(0.80)
	Cash flow	(31.26)	(22.96)	(14.50)	(5.96)	(1.67)	(1.73)	(1.47)	(0.62)	(0.93)	(0.67)
	Capex	(0.35)	(0.71)	(0.28)	(0.01)	(0.02)	(0.01)	(0.05)	(0.08)	0.00	0.00
	Free cash flow	(31.62)	(23.67)	(14.78)	(5.97)	(1.69)	(1.74)	(1.53)	(0.70)	(0.93)	(0.67)
	Book value	37.14	34.82	15.71	6.27	3.44	5.72	2.51	1.69	0.94	0.72
	Shares, m	2	2	2	3	9	19	28	54	74	93
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	—	0.00	0.00	0.00	0.00
	P/S	—	—	—	0.00	3.40	—	5.25	6.21	20.64	6.50
	P/B	—	—	—	0.67	1.13	—	0.94	0.89	3.85	1.08
	EV/Sales	—	—	—	0.00	0.79	—	0.39	(1.03)	15.40	(0.25)
	EV/FCF	—	—	—	0.27	(0.54)	—	(0.12)	0.35	(2.90)	0.05
Cash, $m
Cash, $m	Operating cash flow	(53)	(42)	(31)	(20)	(15)	(33)	(42)	(33)	(69)	(62)
	Capex	(1)	(1)	(1)	0	0	0	(1)	(4)	0	0
	Free cash flow	(53)	(44)	(32)	(20)	(15)	(33)	(43)	(37)	(69)	(62)
Balance, $m
Balance, $m	Working capital	66	77	40	19	30	108	67	87	67	65
	Total debt	10	20	16	2	1	0	1	1	1	0
	Net debt	(63)	(65)	(34)	(29)	(30)	(108)	(65)	(97)	(71)	(78)
	Shareholders’ equity	63	64	34	21	31	109	71	90	70	67
Returns, %
Returns, %	ROA	(55.05)	(56.75)	(48.58)	(53.08)	(43.31)	(43.78)	(42.91)	(46.56)	(58.88)	(78.09)
	ROIC	(18,959.42)	0.00	(15,194.44)	0.00	(847.77)	(1,318.00)	(471.97)	0.00	0.00	0.00
	ROE	(65.06)	(75.89)	(70.52)	(86.34)	(61.80)	(48.03)	(50.26)	(62.30)	(79.88)	(108.11)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
COCP Cocrystal Pharma, Inc.	$19.8M	— (loss-making)	— (loss-making)	−81.05% (below 0%: shrinking)	n/m	−16.75% (below 0%: shrinking)	100.00%	(3,032.38%)	Compare
ATYR aTyr Pharma, Inc.	$18.0M	— (loss-making)	— (loss-making)	−90.75% (below 0%: shrinking)	n/m	+32.22% (above 0%: growing)	100.00%	0.00%
NEUP Neuphoria Therapeutics Inc.	$17.9M	— (loss-making)	— (loss-making)	−107.32% (below 0%: shrinking)	n/m	+133.86% (above 0%: growing)	100.00%	0.00%	Compare
JSPR Jasper Therapeutics, Inc.	$17.7M	— (loss-making)	—	—	n/m	+55.74% (above 0%: growing)	0.00%	0.00%	Compare
ANEB Anebulo Pharmaceuticals, Inc.	$17.6M	— (loss-making)	—	—	n/m	+6.58% (above 0%: growing)	—	0.00%	Compare
ACGN Aceragen, Inc.	$17.1M	— (loss-making)	— (loss-making)	+2,394.95% (above 0%: growing)	n/m	−115.67% (below 0%: shrinking)	100.00%	(834.33%)	Compare
RADX Radiopharm Theranostics Limited - Sponsored ADR	$17.0M	—	—	—	—	−137.75% (below 0%: shrinking)	—	—	Compare
DYAI Dyadic International Inc.	$16.8M	— (loss-making)	— (loss-making)	−0.57% (below 0%: shrinking)	n/m	−1,298.54% (below 0%: shrinking)	(2.39%)	(213.73%)	Compare
PBM Psyence Biomedical Ltd.	$16.5M	0.2×	—	—	n/m	−707.20% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$17.4M	—	—	−40.81%	—	−66.21%	100.00%	0.00%

All 614 Biotechnology stocks →

aTyr Pharma, Inc. (ATYR) key facts

Concern: aTyr Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $190,000.00, down 19.1% from fiscal 2024.
aTyr Pharma, Inc. (ATYR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ATYR traded at $0.17, a market capitalization of $18.0 million.
Return on equity was −108.1% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −9.34 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.